Literature DB >> 24327118

The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.

C Cuerda1, C Velasco1, J Merchán-Naranjo2, P García-Peris1, C Arango2.   

Abstract

Second-generation antipsychotics (SGA) are associated with weight gain and metabolic alterations including hyperglycemia, dyslipidemia, hypertension and metabolic syndrome. These metabolic side effects increase cardiovascular risk and are related to medication non-compliance. Patients without previous exposure to these or other antipsychotic drugs (naive patients) seem to be more prone to develop these metabolic abnormalities. The mechanisms behind weight gain can be an increase in food intake and/or a decrease in energy expenditure. This review comprehensively examines the current knowledge on the impact of these drugs on food intake and energy expenditure. The influence of these drugs on appetite and food intake (total caloric intake and food sources) is reviewed as well as the evidence of abnormal eating behaviors. The studies evaluating the effect on resting energy expenditure are critically examined, taking into account the influence of body composition and previous exposure to antipsychotics (naive vs non-naive patients). Finally, the influence of these drugs on physical activity is also discussed. The knowledge of the mechanisms of weight gain in patients starting these drugs may be useful to further prompt research in this field and ameliorate the metabolic side effects associated with these treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24327118     DOI: 10.1038/ejcn.2013.253

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  53 in total

Review 1.  Antipsychotic drugs and obesity.

Authors:  Christoph U Correll; Todd Lencz; Anil K Malhotra
Journal:  Trends Mol Med       Date:  2010-12-22       Impact factor: 11.951

2.  Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms.

Authors:  Caroline Stokes; Malcolm Peet
Journal:  Nutr Neurosci       Date:  2004-08       Impact factor: 4.994

Review 3.  Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.

Authors:  David Fraguas; Christoph U Correll; Jessica Merchán-Naranjo; Marta Rapado-Castro; Mara Parellada; Carmen Moreno; Celso Arango
Journal:  Eur Neuropsychopharmacol       Date:  2010-08-10       Impact factor: 4.600

4.  A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.

Authors:  James L Roerig; James E Mitchell; Martina de Zwaan; Ross D Crosby; Blake A Gosnell; Kristine J Steffen; Stephen A Wonderlich
Journal:  J Clin Psychopharmacol       Date:  2005-10       Impact factor: 3.153

5.  Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

Authors:  Julio Bobes; Celso Arango; Pedro Aranda; Rafael Carmena; Margarida Garcia-Garcia; Javier Rejas
Journal:  Schizophr Res       Date:  2006-11-21       Impact factor: 4.939

6.  Increased food intake and energy expenditure following administration of olanzapine to healthy men.

Authors:  Robert J Fountaine; Ann E Taylor; James P Mancuso; Frank L Greenway; Lauri O Byerley; Steven R Smith; Marlene M Most; David A Fryburg
Journal:  Obesity (Silver Spring)       Date:  2010-02-04       Impact factor: 5.002

7.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Authors:  Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

8.  Clozapine's effects on body weight and resting metabolic rate: a case series.

Authors:  Ric M Procyshyn; Anthony Chau; Gordon Tse
Journal:  Schizophr Res       Date:  2004-02-01       Impact factor: 4.939

9.  Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

10.  Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.

Authors:  Karen L Teff; Michael R Rickels; Joanna Grudziak; Carissa Fuller; Huong-Lan Nguyen; Karl Rickels
Journal:  Diabetes       Date:  2013-07-08       Impact factor: 9.461

View more
  12 in total

1.  Psychotropic usage by patients presenting to an academic eating disorders program.

Authors:  Karuna Mizusaki; Daniel Gih; Christina LaRosa; Rebekah Richmond; Renee D Rienecke
Journal:  Eat Weight Disord       Date:  2018-06-07       Impact factor: 4.652

2.  Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.

Authors:  Katherine J Motyl; Victoria E DeMambro; Deborah Barlow; David Olshan; Kenichi Nagano; Roland Baron; Clifford J Rosen; Karen L Houseknecht
Journal:  Endocrinology       Date:  2015-04-08       Impact factor: 4.736

Review 3.  Body mass index in dementia.

Authors:  S García-Ptacek; G Faxén-Irving; P Cermáková; M Eriksdotter; D Religa
Journal:  Eur J Clin Nutr       Date:  2014-10-01       Impact factor: 4.016

4.  Implications of Dietary Intake and Eating Behaviors for People with Serious Mental Illness: A Qualitative Study.

Authors:  Annabel S Mueller-Stierlin; Sebastian Cornet; Anna Peisser; Selina Jaeckle; Jutta Lehle; Sabrina Moerkl; Scott B Teasdale
Journal:  Nutrients       Date:  2022-06-24       Impact factor: 6.706

5.  The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.

Authors:  Inmaculada Baeza; Laura Vigo; Elena de la Serna; Rosa Calvo-Escalona; Jessica Merchán-Naranjo; Pamela Rodríguez-Latorre; Celso Arango; Josefina Castro-Fornieles
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-05-21       Impact factor: 4.785

6.  Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain.

Authors:  Rizaldy C Zapata; Olivia Osborn
Journal:  Physiol Behav       Date:  2020-03-07

7.  Food craving and consumption evolution in patients starting treatment with clozapine.

Authors:  Marina Garriga; Andrea Mallorquí; Lourdes Serrano; José Ríos; Manel Salamero; Eduard Parellada; Marta Gómez-Ramiro; Cristina Oliveira; Silvia Amoretti; Eduard Vieta; Miquel Bernardo; Clemente García-Rizo
Journal:  Psychopharmacology (Berl)       Date:  2019-06-13       Impact factor: 4.530

8.  The Relationship between Body Weight Change and Body Constitutions of Traditional Chinese Medicine in Patients with Schizophrenia.

Authors:  Jui-Fen Cheng; Xuan-Yi Huang; Te-Le Liu; Ruey-Yun Wang; Han-Yi Ching
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-13       Impact factor: 2.629

Review 9.  The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.

Authors:  Alex T Raben; Victoria S Marshe; Araba Chintoh; Ilona Gorbovskaya; Daniel J Müller; Margaret K Hahn
Journal:  Front Neurosci       Date:  2018-01-22       Impact factor: 4.677

10.  Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats.

Authors:  Silje Skrede; Ismael González-García; Luís Martins; Rolf Kristian Berge; Ruben Nogueiras; Manuel Tena-Sempere; Gunnar Mellgren; Vidar Martin Steen; Miguel López; Johan Fernø
Journal:  Int J Neuropsychopharmacol       Date:  2017-12-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.